Results 21 to 30 of about 198,185 (239)
IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma
Frontiers in Oncology, 2021 Hepatocellular carcinoma (HCC) is a common malignant tumor of which the occurrence and development, the tumorigenicity of HCC is involving in multistep and multifactor interactions.
Junnv Xu +7 more
doaj +1 more source
Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study [PDF]
Annals of the Rheumatic Diseases, 2009 To evaluate the safety and efficacy of 5-year, long-term tocilizumab monotherapy for patients with rheumatoid arthritis.In an open-label, long-term extension trial following an initial 3-month randomised phase II trial, 143 of the 163 patients who participated in the initial blinded study received tocilizumab monotherapy (8 mg/kg) every 4 weeks ...
Nishimoto, N +5 more
openaire +2 more sources
Frontiers in Immunology, 2022 Interleukin-6 (IL-6), a pleiotropic cytokine that regulates immune responses and inflammatory reactions, plays a pivotal role in the development of rheumatoid arthritis (RA).
Xiaolei Liu +9 more
doaj +1 more source
Frontiers in Immunology, 2023 Commonly used clinical strategies against coronavirus disease 19 (COVID-19), including the potential role of monoclonal antibodies for site-specific targeted drug delivery, are discussed here.
Aleksandra Zielińska +13 more
doaj +1 more source
Hemophagocytic Lymphohistiocytosis: Its Biochemical Basis and Clinical Implications [PDF]
Avicenna Journal of Medical BiochemistryHemophagocytic lymphohistiocytosis (HLH) is a life-threatening syndrome characterized by excessive cytokine activation. Its treatment remains extremely limited, with high mortality.
Sryla Punjadath, Ravi Kant
doaj +1 more source
DRUG-INDUCED ENCEPHALOPATHY WITH IMPAIRED COGNITIVE FUNCTIONS DURING TOCILIZUMAB USE
Научно-практическая ревматология, 2019 Blockade of interleukin-6 (IL-6) is one of the most promising areas in the treatment of a number of immunoinflammatory diseases. Tocilizumab (TCZ), the first registered anti-IL-6 receptor monoclonal antibody, has been used effectively by rheumatologists ...
P. A. Shesternya +5 more
doaj +1 more source
Vaccines, 2021 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the current COVID-19 pandemic, has caused more than 4.5 million deaths worldwide.
Collin Jugler, Haiyan Sun, Qiang Chen
doaj +1 more source
Biochemistry and Biophysics Reports, 2021 Rheumatoid arthritis (RA) is a chronic immune disease characterized by synovitis and bone destruction. The osteoclasts play a critical role in pathologic bone loss during inflammatory arthritis.
Renling Zou, Xiayang Huang, Peng Xu
doaj +1 more source
Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?
Biomedicines, 2022 Systemic sclerosis (SS) is a chronic autoimmune disorder, which has both cutaneous and systemic clinical manifestations. The disease pathogenesis includes a triad of manifestations, such as vasculopathy, autoimmunity, and fibrosis.
Anca Cardoneanu +5 more
doaj +1 more source
Arthritis Research & Therapy, 2019 Objectives Most therapies for autoimmune and inflammatory diseases either neutralize or suppress production of inflammatory cytokines produced by activated macrophages (e.g., TNFα, IL-1, IL-6, IL-17, GM-CSF).
Yingwen Hu +14 more
doaj +1 more source